Thanks ds for the link. One interesting point arising from the research paper;
Page 1 - Introduction: the point is made that with each of the collaboration agreements signed to date, AstraZeneca, Roche, Pfizer and J&J, that each can yield milestone payments in due course.
The inference appears to be that the collaborations are alive and active [rather than run their course and stalled]. What do we make of the language used in the research paper?
Add to My Watchlist
What is My Watchlist?
